Nuveen LLC Takes $28.74 Million Position in Amicus Therapeutics, Inc. $FOLD

Nuveen LLC purchased a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 3,522,217 shares of the biopharmaceutical company's stock, valued at approximately $28,741,000. Nuveen LLC owned approximately 1.14% of Amicus Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of FOLD. Vestal Point Capital LP bought a new position in shares of Amicus Therapeutics in the fourth quarter valued at $31,557,000. Orbimed Advisors LLC increased its holdings in shares of Amicus Therapeutics by 300.7% in the fourth quarter. Orbimed Advisors LLC now owns 2,285,400 shares of the biopharmaceutical company's stock valued at $21,528,000 after buying an additional 1,715,100 shares in the last quarter. Rock Springs Capital Management LP increased its holdings in shares of Amicus Therapeutics by 107.9% in the fourth quarter. Rock Springs Capital Management LP now owns 2,599,425 shares of the biopharmaceutical company's stock valued at $24,487,000 after buying an additional 1,349,145 shares in the last quarter. Prosight Management LP acquired a new stake in Amicus Therapeutics during the 4th quarter valued at $8,666,000. Finally, D. E. Shaw & Co. Inc. raised its stake in Amicus Therapeutics by 132.7% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,560,410 shares of the biopharmaceutical company's stock valued at $14,699,000 after purchasing an additional 889,968 shares during the period.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on FOLD shares. Wall Street Zen raised shares of Amicus Therapeutics from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. The Goldman Sachs Group cut their target price on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating on the stock in a research note on Friday, May 2nd. UBS Group boosted their target price on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Finally, Morgan Stanley raised shares of Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a research note on Thursday, July 17th. Eight analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat.com, Amicus Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $16.22.

Amicus Therapeutics Stock Up 0.6%

FOLD stock traded up $0.0450 during mid-day trading on Friday, hitting $7.6450. The stock had a trading volume of 924,063 shares, compared to its average volume of 3,861,493. Amicus Therapeutics, Inc. has a 1-year low of $5.51 and a 1-year high of $12.65. The company has a fifty day moving average of $6.32 and a 200 day moving average of $7.21. The company has a current ratio of 3.21, a quick ratio of 2.29 and a debt-to-equity ratio of 1.92. The stock has a market capitalization of $2.36 billion, a price-to-earnings ratio of -63.79 and a beta of 0.53.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.